Loading...
Anti-HER2/Neu passive-aggressive immunotherapy
Preclinical studies have established that CD8(+) T cells are necessary for efficient immunotherapeutic regimens targeting v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2, best known as HER2/Neu). Recently, we extended upon these findings by demonstrating that anti-HER2/Neu the...
Na minha lista:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Landes Bioscience
2014
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3935925/ https://ncbi.nlm.nih.gov/pubmed/24605268 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.27296 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|